VirtualScopics (VSCP) 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'VirtualScopics, Inc.	'
Entity Central Index Key	'0001307752	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'VSCP	'
Entity Common Stock, Shares Outstanding	'	2,994,928
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash	$5,573,576	$7,330,630
Accounts receivable, net	1,861,735	1,725,070
Prepaid expenses and other current assets	371,341	397,699
Total current assets	7,806,652	9,453,399
Patents, net	1,271,586	1,334,420
Property and equipment, net	261,608	221,700
Total assets	9,339,846	11,009,519
Current liabilities	'	'
Accounts payable and accrued expenses	840,540	846,071
Accrued payroll	685,595	837,611
Unearned revenue	588,187	745,028
Dividends payable	335,333	293,333
Total current liabilities	2,449,655	2,722,043
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Common stock, $0.001 par value; 20,000,000 and 85,000,000 shares authorized at June 30, 2014 and December 31, 2013, respectively; issued 2,992,853 shares at June 30, 2014 and December 31, 2013, respectively; outstanding, 2,992,853 and 2,991,869 shares at June 30, 2014 and December 31, 2013, respectively	2,993	2,992
Additional paid-in capital	21,973,237	21,992,619
Accumulated deficit	-15,086,045	-13,708,141
Total stockholders' equity	6,890,191	8,287,476
Total liabilities and stockholders' equity	9,339,846	11,009,519
Convertible Preferred Stock Series A [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	2	2
Convertible Preferred Stock Series B [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	1	1
Convertible Preferred Stock Series C - 1 [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	3	3
Convertible Preferred Stock Series C - 2 [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2014	Dec. 31, 2013
Convertible preferred stock, par value (in dollars per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	1,000,000	15,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	20,000,000	85,000,000
Common stock, shares issued	2,992,853	2,992,853
Common stock, shares outstanding	2,992,853	2,991,869
Convertible Preferred Stock Series A [Member]	'	'
Convertible preferred stock, shares authorized	8,400	8,400
Convertible preferred stock, shares issued	2,190	2,190
Convertible preferred stock, shares outstanding	2,190	2,190
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series B [Member]	'	'
Convertible preferred stock, shares authorized	6,000	6,000
Convertible preferred stock, shares issued	600	600
Convertible preferred stock, shares outstanding	600	600
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series C - 1 [Member]	'	'
Convertible preferred stock, shares authorized	3,000	3,000
Convertible preferred stock, shares issued	3,000	3,000
Convertible preferred stock, shares outstanding	3,000	3,000
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series C - 2 [Member]	'	'
Convertible preferred stock, shares authorized	3,000	3,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues	$2,542,048	$3,546,607	$4,789,001	$5,829,438
Reimbursement revenues	106,699	160,070	212,731	409,826
Total revenues	2,648,747	3,706,677	5,001,732	6,239,264
Cost of services	1,601,679	1,776,524	3,090,758	3,274,063
Cost of reimbursement revenues	106,699	160,070	212,731	409,826
Total cost of services	1,708,378	1,936,594	3,303,489	3,683,889
Gross profit	940,369	1,770,083	1,698,243	2,555,375
Operating expenses	'	'	'	'
Research and development	306,289	349,754	592,185	803,164
Sales and marketing	482,807	430,153	827,884	787,805
General and administrative	807,642	777,354	1,494,643	1,772,656
Depreciation and amortization	75,526	90,554	162,028	186,867
Total operating expenses	1,672,264	1,647,815	3,076,740	3,550,492
Operating (loss) income	-731,895	122,268	-1,378,497	-995,117
Other income (expense)	'	'	'	'
Other income	1,051	12,425	2,057	18,304
Other expense	-687	-407	-1,464	-1,848
Total other income	364	12,018	593	16,456
Net (loss) income	-731,531	134,286	-1,377,904	-978,661
Preferred stock dividends	42,000	42,000	84,000	84,000
Net (loss) income available to common stockholders	($773,531)	$92,286	($1,461,904)	($1,062,661)
Weighted average basic shares outstanding (in shares)	2,992,853	2,979,952	2,992,421	2,979,952
Weighted average diluted shares outstanding (in shares)	2,992,853	3,467,138	2,992,421	2,979,952
Basic and diluted (loss) earnings per share (in dollars per share)	($0.26)	$0.03	($0.49)	($0.36)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities	'	'
Net loss	($1,377,904)	($978,661)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	162,028	186,867
Loss on the disposal of assets	0	9,862
Stock-based compensation	64,619	252,307
Changes in operating assets and liabilities	'	'
Accounts receivable	-136,665	-1,206,490
Prepaid expenses and other assets	26,358	131,441
Accounts payable and accrued expenses	-5,531	-126,610
Accrued payroll	-152,016	182,590
Unearned revenue	-156,841	174,205
Total adjustments	-198,048	-395,828
Net cash used in operating activities	-1,575,952	-1,374,489
Cash flows from investing activities	'	'
Purchases of property and equipment	-133,078	-25,198
Proceeds from the sale of equipment	0	28,441
Patent applications and maintenance	-6,024	-6,818
Net cash used in investing activities	-139,102	-3,575
Cash flows from financing activities	'	'
Cash dividends on series B preferred stock	-42,000	0
Net cash used in financing activities	-42,000	0
Net decrease in cash	-1,757,054	-1,378,064
Cash	'	'
Beginning of period	7,330,630	8,523,807
End of period	5,573,576	7,145,743
Non-cash financing activity:	'	'
Accrued dividends on series B and C-1 preferred stock	$42,000	$84,000

Nature_of_Business_and_Basis_o

Nature of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Organization and Basis Of Presentation [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	NOTE 1 - Nature of Business and Basis of Presentation
	Nature of Business
	The headquarters of VirtualScopics. Inc. and its wholly-owned subsidiary, VirtualScopics, LLC (the “Subsidiary” and, together, the “Company”) are located in Rochester, New York. The Company has created a suite of image analysis software tools and applications which are used in detecting and measuring specific anatomical structures and metabolic activity using medical images. The Company’s developed proprietary software provides measurement capabilities designed to improve pharmaceutical and medical device research and development and improve clinical medical image analysis.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information pursuant to article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for condensed financial statements and should be read in conjunction with the audited consolidated financial statements and notes related thereto contained in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2013. In the opinion of management, these financial statements contain all adjustments necessary for a fair presentation for and as of the end of the interim period, all of which were normal recurring adjustments. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the full year ending December 31, 2014.
	A Certificate of Amendment to effect a reverse stock split was approved by the Company's stockholders at its Annual Meeting of Stockholders held on August 13, 2013.  The Company's stockholders granted the Board authority to effectuate a reverse stock split at a ratio of between 1-for-2 to 1-for-10. The Company’s Board of Directors subsequently approved a 1-for-10 reverse stock split of the Company’s outstanding common stock that was effected on August 21, 2013. Corresponding adjustments were made to the number of shares of common stock underlying the Company’s outstanding options, warrants, and preferred stock exercisable for or convertible into common stock and the related long-term incentive plans for such options. All share and related option information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the reduced number of shares resulting from this action.
	Additionally, a Certificate of Amendment to decrease the Company’s authorized common stock from 85,000,000 shares to 20,000,000 shares and to decrease the number of authorized and undesignated preferred stock from 15,000,000 shares to 1,000,000 shares was approved by the Company's stockholders at its Annual Meeting of Stockholders held on June 17, 2014. The authorized share information presented in these financial statements and accompanying footnotes will reflect the change as of June 30, 2014 and going forward.

Summary_of_Certain_Significant

Summary of Certain Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 2 - Summary of Certain Significant Accounting Policies
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of the Company and the Subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.
	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services and products have been performed or delivered, as the case may be, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any.
	The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged at an hourly rate.
	Occasionally, the Company has provided software development services to its customers, which may require development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software licenses, upgrades or enhancements, or post-contract customer services.
	Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as revenue and cost of services, respectively, in the financial statements.
	Income Taxes
	In its interim financial statements, the Company follows the guidance of Accounting Standards Codification (“ASC”) 270 “Interim Reporting” and ASC 740 “Income Taxes” whereby it uses the expected annual effective tax rate in determining its interim tax provisions. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized based upon the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
	Research and Development
	Research and development expense relates to the development of new applications and processes including improvements and enhancements to existing software applications. These costs are expensed as incurred.
	Reclassifications
	The Company has reclassified certain amounts from its previously reported condensed consolidated financial statements for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications had no impact on the Company’s previously reported condensed consolidated results from operations or cash flows.
	Fair Value of Financial Instruments
	Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy.
	Recent Accounting Pronouncements
	The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
	The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supercedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 3 - Stock-Based Compensation
	For the three and six months ended June 30, 2014 and 2013, the Company’s condensed consolidated statements of operations reflect stock-based compensation expense for stock options granted under its long-term incentive plans and allocated as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Cost of service revenues	$	9,223		$	12,371		$	20,264	$	25,214
	Research and development		8,912			16,331			18,485		35,896
	Sales and marketing		2,046			2,780			4,737		5,823
	General and administrative		3,050			72,692			20,574		173,022
	Total stock-based compensation	$	23,231		$	104,174		$	64,060	$	239,955
	Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal but no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a three or four-year period. As of June 30, 2014, there was $129,755 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted-average period of 2 years.
	The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The risk free interest rate is based on U.S. Treasury zero-coupon yield curve over the expected term of the option. The expected term assumption is determined using the weighted average midpoint between the vesting and expiration term for all individuals within the grant. The Company estimated its expected volatility using its own historical stock prices. The Company’s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock. The Company’s model does not include a discount for post-vesting restrictions, as the Company has not issued awards with such restrictions. The periodic expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company’s estimate of pre-vesting forfeitures is primarily based on the Company’s historical experience and is adjusted to reflect actual forfeitures as the options vest. The following assumptions were used to estimate the fair value of options granted for the six months ended June 30, 2014 and 2013 using the Black-Scholes option-pricing model:
		June 30,
		2014				2013
	Risk free interest rate		1.8	%			1.3	%
	Expected term (years)		5.9				6.6
	Expected volatility		65.8	%			68.3	%
	Expected dividend yield		-				-
	A summary of the employee stock option activity for the six months ended June 30, 2014 is as follows:
		Number of			Weighted			Weighted
		Shares			Average			Average
					Exercise			Remaining
					Price			Contractual
								Term
	Options outstanding at January 1, 2014		425,875		$	12.72
	Granted		16,750			3.47
	Exercised		-
	Cancelled/Forfeited		-197,363			-10.18
	Expired		-316			-23.6
	Options outstanding at June 30, 2014		244,946			14.16			4.53
	Options exercisable at June 30, 2014		207,532			15.1			3.82
	As of June 30, 2014 and 2013, the Company had options outstanding to consultants of 0 and 5,344, respectively.
	The weighted-average grant-date fair value of options granted during the six months ended June 30, 2014 and 2013 was $41,368 and $5,632, respectively.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 4 - Stockholders’ Equity
	As of June 30, 2014, the Company has authorized 1,000,000 shares of preferred stock, par value $0.001 per share, of which 8,400 are designated as Series A Convertible Preferred Stock (“Series A”), 6,000 are designated as Series B Convertible Preferred Stock (“Series B”), 3,000 are designated as Series C-1 Convertible Preferred Stock (“Series C-1”), and 3,000 are designated as Series C-2 Convertible Preferred Stock (“Series C-2”) as specified in the Certificate of Designation (the “Certificate”). During the six months ended June 30, 2014 and 2013, there were no conversions of the Company’s convertible preferred stock.
	Each share of Series A is convertible into 83.036 shares of the Company’s common stock and is senior in liquidation preference in comparison to shares of the Company’s common stock.
	Each share of Series B is convertible into 83.036 shares of the Company’s common stock and has a liquidation preference that is pari passu with the Company’s Series A and senior to the Company’s common stock. Cumulative dividends on the Series B accrue on the stated value of $1,000 per share at an annual rate of 8%, payable monthly in cash and/or shares of the Company’s common stock at the option of the Company. Subject to certain exceptions, the Series B holders are only entitled to be paid dividends if full dividends are first paid or concurrently paid to the holders of the Series C-1. As of June 30, 2014 and December 31, 2013, there were $96,000 and $84,000, respectively of accrued dividends payable to Series B stockholders. During the six months ended June 30, 2014 and 2013, cash dividends paid to Series B stockholders aggregated to $12,000 and $0, respectively.
	Each share of Series C-1 is convertible into shares of the Company’s common stock at a conversion rate determined by dividing (i) the stated value per share of $1,000, plus, if consented to by the Company, all accrued and unpaid dividends, by (ii) the conversion price of $12.043. The Series C-1 is senior in liquidation preference in comparison to shares of the Company’s common stock and the Series A and Series B preferred stock. Cumulative dividends on the Series C accrue on the stated value of $1,000 per share at an annual rate of 4%. As of June 30, 2014 and December 31, 2013, there were $239,333 and $209,333, respectively of accrued dividends payable to Series C-1 stockholders. During the six months ended June 30, 2014 and 2013, cash dividends paid to Series C-1 stockholders aggregated to $30,000 and $0, respectively.
	Restricted Stock Awards
	A restricted stock award entitles the recipient to receive shares of unrestricted common stock upon vesting of the award and expiration of certain restrictions contained in the grant of such award. The fair value of each restricted stock award is determined upon granting of the shares and the related compensation expense is recognized ratably over the vesting period and charged to the operations as non-cash compensation expense. Shares contained in the unvested portion of restricted stock awards are forfeited upon termination of employment, unless otherwise agreed. The fair value of restricted stock issued under the Plan is determined based on the closing price of the Company’s common stock on the grant date.
	A summary of the restricted stock award activity for the six months ended June 30, 2014 is as follows:
		Number		Weighted
		of Units		Average
				Grant
				Date Fair
				Value
	Nonvested at January 1, 2014		984		7.4
	Granted		-
	Vested		-984		-7.4
	Cancelled/Forfeited		-
	Nonvested at June 30, 2014		-
	The Company incurred $559 and $12,352 in compensation expense during the six months ended June 30, 2014 and 2013, respectively, and 0 and $7,346 in compensation expense during the three months ended June 30, 2014 and 2013, respectively, related to the restricted stock awards granted to Board members and former officers of the Company. During the six months ended June 30, 2014, 984 restricted stock units vested as part of the former CFO’s consulting agreement.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 5 – Earnings (Loss) Per Share
	Basic earnings and loss per share are computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible preferred stock and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, the exercise of stock options and warrants from the calculation of net loss per share as their effect would be antidilutive.
	The following table reconciles the numerator and denominator for the calculation:
		For the three months ended				For the six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Net (loss) income available to common stockholders – basic	$	-773,531	$	92,286	$	-1,461,904	$	-1,062,661
	Denominator - basic:
	Weighted average number of common shares outstanding		2,992,853		2,979,952		2,992,421		2,979,952
	Basic (loss) earnings per common share	$	-0.26	$	0.03	$	-0.49	$	-0.36
	Net (loss) income available to common stockholders - diluted	$	-773,531	$	92,286	$	-1,461,904	$	-1,062,661
	Denominator - diluted:
	Weighted average number of common shares outstanding		2,992,853		2,979,952		2,992,421		2,979,952
	Common share equivalents of outstanding stock options		-		6,409		-		-
	Common share equivalents of outstanding stock convertible preferred stock		-		480,777		-		-
	Weighted average number of common shares outstanding		2,992,853		3,467,138		2,992,421		2,979,952
	Diluted (loss) earnings per common share	$	-0.26	$	0.03	$	-0.49	$	-0.36
	Securities excluded from the weighted average dilutive common shares outstanding because their inclusion would have been antidilutive:
	Convertible preferred stock		480,777		-		480,777		480,777
	Non-vested restricted stock awards		-		15,927		-		15,927
	Stock options to purchase common stock		244,946		575,907		244,946		582,307
	Warrants to purchase common stock		233,753		233,753		233,753		233,753

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 6 - Income Taxes
	The Company has significant net operating loss and business credit carryovers which are subject to a valuation allowance due to the uncertain nature of the realization of the losses. The Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control. The Company does not believe it has encountered ownership changes which could significantly limit the possible utilization of such carryovers. It is not anticipated that limitations, if any, would have a material impact on the condensed consolidated balance sheet as a result of offsetting changes in the deferred tax valuation allowance. Based on all available evidence, the Company believes that its deferred tax assets should be fully reserved as of June 30, 2014 because it is still currently more likely than not that the benefits of the Company’s deferred tax assets will not be realized in future periods. The Company will continue to assess the likelihood of recognizing a portion of its deferred tax assets and will make an assessment of whether it should reduce the valuation allowance.
	The Company will recognize interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. As of June 30, 2014, the Company does not have any interest and penalties accrued related to unrecognized tax benefits.

Concentration_of_Credit_Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	NOTE 7 - Concentration of Credit Risk
	The Company’s top four customers accounted for approximately 30%, 20%, 18%, and 10% of total revenue for the six months ended June 30, 2014. Three customers accounted for 48%, 10%, and 10% of total revenue for the six months ended June 30, 2013.
	The Company’s top four customers accounted for approximately 28%, 22%, 18%, and 13% of total revenue for the three months ended June 30, 2014. Two customers accounted for 58% and 10% of total revenue for the three months ended June 30, 2013.
	Four customers accounted for approximately 25%, 19%, 16%, and 15% of accounts receivable as of June 30, 2014. Four customers accounted for approximately 34%, 13%, 13%, and 11% of accounts receivable as of December 31, 2013.

Related_Party

Related Party	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 8 – Related Party
	In April 2012, the Company issued Merck Global Health Innovation Fund, LLC (“Merck”) 3,000 shares of Series C-1 which are convertible into 249,107 shares of common stock and Series C-1 Warrants which are exercisable to purchase 136,132 shares of common stock. . Revenues generated from Merck were $42,755 and $129,435 for the six months ended June 30, 2014 and 2013, respectively and $19,640 and $33,792 for the three months ended June 30, 2014 and 2013, respectively. The accounts receivable balance due from Merck was $7,225 and $87,200 as of June 30, 2014 and December 31, 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 9 – Commitments and Contingencies
	In May 2014, the Company entered into a lease for approximately 2,190 square feet of office space in New Hope, Pennsylvania. The lease term is for three years with a lease commencement date of June 1, 2014. The base annual rent under the lease is $54,000, and increases three percent (3%) per year over the term of the lease.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 10 - Subsequent Events
	On July 23, 2014, (the “Effective Date”), the Company entered into an employment agreement with Eric T. Converse who was appointed President and Chief Executive Officer. The Executive Employment Agreement begins as of the Effective Date, has an initial term of one year and will be extended automatically for one-year periods so long as Mr. Converse remains fully employed by the Company. Mr. Converse will receive an annual salary of $325,000 during the term of the Executive Employment Agreement. Mr. Converse is also eligible to receive an annual incentive bonus tied to the achievement of Company goals approved by the Compensation Committee of the Company’s Board of Directors. Mr. Converse is eligible to participate in such health, medical and dental, disability and other executive benefit plans as are afforded to other executive officers of the Company. On the Effective Date, Mr. Converse was granted an option to purchase 87,017 shares of the Company’s common stock with a $4.22 exercise price, four year vesting period, and ten year term. If Mr. Converse remains employed by the Company on the date that is twelve months after the Effective Date, the Company will award an option to purchase an additional 87,017 shares, and if employed twenty-four months after the Effective Date, then the Company will also award an option to purchase an additional 43,510 shares. Each award is subject to the terms of the Company’s Amended and Restated 2006 Long-Term Incentive Plan. The options will vest at the rate of 25% on each anniversary of each award while Mr. Converse is employed by the Company.
	The Executive Employment Agreement provides that if the Company terminates Mr. Converse’s employment without cause, then the Company is required to pay his annual salary and benefits for a period of six months. If a Change in Control (as defined in the Executive Employment Agreement) occurs on or before the third anniversary of the Effective Date, then the Company is required to pay Mr. Converse an amount equal to 75% of his annual salary for the year in which the Change in Control occurs.

Summary_of_Certain_Significant1

Summary of Certain Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of the Company and the Subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services and products have been performed or delivered, as the case may be, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any.
	The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged at an hourly rate.
	Occasionally, the Company has provided software development services to its customers, which may require development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software licenses, upgrades or enhancements, or post-contract customer services.
	Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as revenue and cost of services, respectively, in the financial statements.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	In its interim financial statements, the Company follows the guidance of Accounting Standards Codification (“ASC”) 270 “Interim Reporting” and ASC 740 “Income Taxes” whereby it uses the expected annual effective tax rate in determining its interim tax provisions. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized based upon the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development expense relates to the development of new applications and processes including improvements and enhancements to existing software applications. These costs are expensed as incurred.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	The Company has reclassified certain amounts from its previously reported condensed consolidated financial statements for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications had no impact on the Company’s previously reported condensed consolidated results from operations or cash flows.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
	The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supercedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	For the three and six months ended June 30, 2014 and 2013, the Company’s condensed consolidated statements of operations reflect stock-based compensation expense for stock options granted under its long-term incentive plans and allocated as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Cost of service revenues	$	9,223		$	12,371		$	20,264	$	25,214
	Research and development		8,912			16,331			18,485		35,896
	Sales and marketing		2,046			2,780			4,737		5,823
	General and administrative		3,050			72,692			20,574		173,022
	Total stock-based compensation	$	23,231		$	104,174		$	64,060	$	239,955
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	The following assumptions were used to estimate the fair value of options granted for the six months ended June 30, 2014 and 2013 using the Black-Scholes option-pricing model:
		June 30,
		2014				2013
	Risk free interest rate		1.8	%			1.3	%
	Expected term (years)		5.9				6.6
	Expected volatility		65.8	%			68.3	%
	Expected dividend yield		-				-
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	A summary of the employee stock option activity for the six months ended June 30, 2014 is as follows:
		Number of			Weighted			Weighted
		Shares			Average			Average
					Exercise			Remaining
					Price			Contractual
								Term
	Options outstanding at January 1, 2014		425,875		$	12.72
	Granted		16,750			3.47
	Exercised		-
	Cancelled/Forfeited		-197,363			-10.18
	Expired		-316			-23.6
	Options outstanding at June 30, 2014		244,946			14.16			4.53
	Options exercisable at June 30, 2014		207,532			15.1			3.82

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule Of Share Based Compensation Non Vested Stock Options Activity [Table Text Block]	'
	A summary of the restricted stock award activity for the six months ended June 30, 2014 is as follows:
		Number		Weighted
		of Units		Average
				Grant
				Date Fair
				Value
	Nonvested at January 1, 2014		984		7.4
	Granted		-
	Vested		-984		-7.4
	Cancelled/Forfeited		-
	Nonvested at June 30, 2014		-

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following table reconciles the numerator and denominator for the calculation:
		For the three months ended				For the six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Net (loss) income available to common stockholders – basic	$	-773,531	$	92,286	$	-1,461,904	$	-1,062,661
	Denominator - basic:
	Weighted average number of common shares outstanding		2,992,853		2,979,952		2,992,421		2,979,952
	Basic (loss) earnings per common share	$	-0.26	$	0.03	$	-0.49	$	-0.36
	Net (loss) income available to common stockholders - diluted	$	-773,531	$	92,286	$	-1,461,904	$	-1,062,661
	Denominator - diluted:
	Weighted average number of common shares outstanding		2,992,853		2,979,952		2,992,421		2,979,952
	Common share equivalents of outstanding stock options		-		6,409		-		-
	Common share equivalents of outstanding stock convertible preferred stock		-		480,777		-		-
	Weighted average number of common shares outstanding		2,992,853		3,467,138		2,992,421		2,979,952
	Diluted (loss) earnings per common share	$	-0.26	$	0.03	$	-0.49	$	-0.36
	Securities excluded from the weighted average dilutive common shares outstanding because their inclusion would have been antidilutive:
	Convertible preferred stock		480,777		-		480,777		480,777
	Non-vested restricted stock awards		-		15,927		-		15,927
	Stock options to purchase common stock		244,946		575,907		244,946		582,307
	Warrants to purchase common stock		233,753		233,753		233,753		233,753

Nature_of_Business_and_Basis_o1

Nature of Business and Basis of Presentation (Details Textual)	0 Months Ended
	Aug. 21, 2013	Jun. 30, 2014	Dec. 31, 2013
Stockholders Equity, Reverse Stock Split	'1-for-10	'	'
Common Stock, Shares Authorized	'	20,000,000	85,000,000
Preferred Stock, Shares Authorized	'	1,000,000	15,000,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock-based compensation	$23,231	$104,174	$64,060	$239,955
Cost of service revenues [Member]	'	'	'	'
Stock-based compensation	9,223	12,371	20,264	25,214
Research and development [Member]	'	'	'	'
Stock-based compensation	8,912	16,331	18,485	35,896
Sales and marketing [Member]	'	'	'	'
Stock-based compensation	2,046	2,780	4,737	5,823
General and administrative [Member]	'	'	'	'
Stock-based compensation	$3,050	$72,692	$20,574	$173,022

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Risk free interest rate	1.80%	1.30%
Expected term (years)	'5 years 10 months 24 days	'6 years 7 months 6 days
Expected volatility	65.80%	68.30%
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	6 Months Ended
	Jun. 30, 2014
Options outstanding - Number of Shares at January 1, 2014	425,875
Granted - Number of Shares	16,750
Exercised - Number of Shares	0
Cancelled/Forfeited - Number of Shares	-197,363
Expired - Number of Shares	-316
Options outstanding - Number of Shares at June 30, 2014	244,946
Options exercisable - Number of Shares at June 30, 2014	207,532
Beginning balance, Options outstanding - Weighted Average Exercise Price	$12.72
Granted - Weighted Average Exercise Price	$3.47
Cancelled/Forfeited - Weighted Average Exercise Price	($10.18)
Expired - Weighted Average Exercise Price	($23.60)
Ending balance, Options outstanding - Weighted Average Exercise Price	$14.16
Options exercisable - Weighted Average Exercise Price	$15.10
Options outstanding - Weighted Average Remaining Life (Years)	'4 years 6 months 11 days
Options exercisable - Weighted Average Remaining Contractual Term (in years)	'3 years 9 months 25 days

StockBased_Compensation_Detail3

Stock-Based Compensation (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Share Based Compensation Options Grants In Period Weighted Average Grant Date Fair Value	$41,368	$5,632	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$129,755	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	244,946	'	425,875
Consultant [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	0	5,344	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Non-vested, Number of Units	984
Granted, Number of Units	0
Vested, Number of Units	-984
Cancelled/Forfeited, Number of Units	0
Non-vested, Number of Units	0
Weighted Average Grant Date Fair Value, Non-Vested (in dollars per share)	$7.40
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	($7.40)

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Convertible preferred stock, shares authorized	1,000,000	'	1,000,000	'	15,000,000
Preferred Stock, Par or Stated Value Per Share	$0.00	'	$0.00	'	$0.00
Cash dividends on preferred stock	'	'	$42,000	$0	'
Stock-based compensation	23,231	104,174	64,060	239,955	'
Chief Financial Officer [Member]	'	'	'	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	'	'	984	'	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'	'
Stock-based compensation	0	7,346	559	12,352	'
Series A Convertible Preferred Stock [Member]	'	'	'	'	'
Preferred Stock Designated During Period Shares	'	'	8,400	'	'
Stock Conversion Ratio	'	'	83.036	'	'
Series C-1 Convertible Preferred Stock [Member]	'	'	'	'	'
Preferred Stock Designated During Period Shares	'	'	3,000	'	'
Preferred Stock, Liquidation Preference Per Share	$1,000	'	$1,000	'	'
Preferred Stock Conversion Price Per Share	$12.04	'	$12.04	'	'
Interest and Dividends Payable, Total	239,333	'	239,333	'	209,333
Cash dividends on preferred stock	'	'	30,000	0	'
Preferred Stock, Dividend Rate, Percentage	'	'	4.00%	'	'
Series C-2 Convertible Preferred Stock [Member]	'	'	'	'	'
Convertible preferred stock, shares authorized	3,000	'	3,000	'	3,000
Preferred Stock Designated During Period Shares	'	'	3,000	'	'
Preferred Stock, Liquidation Preference Per Share	$1,000	'	$1,000	'	$1,000
Series B Convertible Preferred Stock [Member]	'	'	'	'	'
Preferred Stock Designated During Period Shares	'	'	6,000	'	'
Preferred Stock, Liquidation Preference Per Share	$1,000	'	$1,000	'	'
Interest and Dividends Payable, Total	96,000	'	96,000	'	84,000
Stock Conversion Ratio	'	'	83.036	'	'
Annual Dividend Rate	'	'	8.00%	'	'
Cash dividends on preferred stock	'	'	$12,000	$0	'

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net (loss) income available to common stockholders - basic	($773,531)	$92,286	($1,461,904)	($1,062,661)
Denominator - basic:	'	'	'	'
Weighted average number of common shares outstanding	2,992,853	2,979,952	2,992,421	2,979,952
Basic (loss) earnings per common share	($0.26)	$0.03	($0.49)	($0.36)
Net (loss) income available to common stockholders - diluted	($773,531)	$92,286	($1,461,904)	($1,062,661)
Denominator - diluted:	'	'	'	'
Weighted average number of common shares outstanding	2,992,853	2,979,952	2,992,421	2,979,952
Common share equivalents of outstanding stock options	0	6,409	0	0
Common share equivalents of outstanding stock convertible preferred stock	0	480,777	0	0
Weighted average number of common shares outstanding	2,992,853	3,467,138	2,992,421	2,979,952
Diluted (loss) earnings per common share	($0.26)	$0.03	($0.49)	($0.36)
Convertible preferred stock [Member]	'	'	'	'
Denominator - diluted:	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	480,777	0	480,777	480,777
Non-vested restricted stock awards [Member]	'	'	'	'
Denominator - diluted:	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	15,927	0	15,927
Stock options to purchase common stock [Member]	'	'	'	'
Denominator - diluted:	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	244,946	575,907	244,946	582,307
Warrants To Purchase Common Stock [Member]	'	'	'	'
Denominator - diluted:	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	233,753	233,753	233,753	233,753

Concentration_of_Credit_Risk_D

Concentration of Credit Risk (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Customer 1 [Member]	'	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	25.00%	'	25.00%	'	34.00%
Concentration Risk, Percentage	28.00%	58.00%	30.00%	48.00%	'
Customer 2 [Member]	'	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	19.00%	'	19.00%	'	13.00%
Concentration Risk, Percentage	22.00%	10.00%	20.00%	10.00%	'
Customer 3 [Member]	'	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	16.00%	'	16.00%	'	13.00%
Concentration Risk, Percentage	18.00%	'	18.00%	10.00%	'
Customer 4 [Member]	'	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	15.00%	'	15.00%	'	11.00%
Concentration Risk, Percentage	13.00%	'	10.00%	'	'

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Common stock issuable upon conversion of preferred stock	249,107	'	'	'	'	'
Revenue from Related Parties	'	$19,640	$33,792	$42,755	$129,435	'
Accounts Receivable, Related Parties	'	$7,225	'	$7,225	'	$87,200
Series C-1 Preferred Stock [Member]	'	'	'	'	'	'
Preferred Stock and Warrant Purchase Agreement Shares Issued	3,000	'	'	'	'	'
Series C-1 Warrants [Member]	'	'	'	'	'	'
Preferred Stock and Warrant Purchase Agreement, Warrants Issued To Acquire Common Stock Shares, Number	136,132	'	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	6 Months Ended
	31-May-14	Jul. 30, 2014	Jun. 30, 2014
Leasing Space Square Feet	'2,190	'	'
Base Annual Rent	'	'	$54,000
Rent Increased Percentage	'	3.00%	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	6 Months Ended	1 Months Ended
	Jun. 30, 2014	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2014
		Subsequent Event [Member]	Employment Agreement [Member]	Employment Contracts [Member]
			Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'
Salaries, Wages and Officers' Compensation	'	'	$325,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	'	87,017
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$3.47	'	'	$4.22
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	'	43,510	'	'
Share Based Compensation Arrangement By Share Based Payment Award Option Vesting Percentage	'	25.00%	'	'
Salaries Wages And Officers Compensation Percentage	'	75.00%	'	'